Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 ...(and advancingour preclinical pipeline wh...),Health

Date:12/3/2008

and advancing our preclinical pipeline, while maintaining a strong balance sheet. We have established important commercial agreements in the non-therapeutic aspects of our technology with Dow Agrosciences in plant agriculture and Sigma-Aldrich Corporation in research reagents. We also have agreements with Genentech and Pfizer in cell-line engineering. We plan to establish strategic partnerships around our therapeutic programs at points of value inflection and expect 2009 to be another year of significant accomplishments for Sangamo."

Mr. Lanphier continued, "We are pursuing a broad development program for our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) with three Phase 2 clinical trials ongoing for the treatment of diabetic neuropathy (DN) and one to evaluate its use in the treatment of amyotrophic lateral sclerosis (ALS). We have also advanced our preclinical pipeline and expect to file Investigational New Drug (IND) application for the first of our ZFN-based therapeutic programs for HIV/AIDS before the end of 2008.

"We are very pleased by the progress of our non-therapeutic collaborations this year. Our partner Sigma-Aldrich successfully launched the CompoZr brand of ZFN-based gene editing tools and we look forward to the increased interest and further validation of the technology that this broadening of the user-base will bring. We also transitioned ahead of schedule into the commercial phase of our collaboration with Dow AgroSciences (DAS) to apply our ZFP technology for plant agriculture and expect DAS to begin to sublicense the technology in that industry. The success of these activities is key to further enhancing the market-leading presence for our technology. We believe that our progress in advancing our technology platform, which is unique in its generation of novel, highly differentiated therapies and products, will create interest among potential pharmace
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System